Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioZ gains local coverage

This article was originally published in The Gray Sheet

Executive Summary

CardioDynamics snags expanded coverage of its BioZ impedance cardiography (ICG) technology with policy reversals from two local Medicare contractors, the firm announces Aug. 7. The contractors for patients in Mississippi, Alabama, Georgia and South Carolina will now cover the noninvasive test to guide treatment of high blood pressure. CMS denied national coverage of the hypertension indication in a November 2006 decision, but left discretion up to local carriers (1"The Gray Sheet" Nov. 27, 2006, In Brief). According to CEO Michael Perry, the firm has "begun to experience a recovery in its ICG business" during the past two quarters...

You may also be interested in...



CMS not convinced by BioZ data

CMS Nov. 20 finalizes its proposed decision not to expand national coverage of CardioDynamics' BioZ transthoracic electrical bioimpedance test to guide treatment of drug-resistant hypertension. "The absence of a direct link from the intervention to the reported outcome is at the core of our reservations about the CONTROL trial," upon which the firm based its request, CMS writes. The agency provides guidelines as to what a more convincing trial might look like, including longer follow-up and tighter protocols. CardioDynamics says it will develop another hypertension study (1"The Gray Sheet" Sept. 4, 2006, p. 17)...

Sun's Halol Site Faces FDA Action

FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.

Dr Reddy’s And Hikma Win Big On US Vascepa Patents

In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.

UsernamePublicRestriction

Register

MT025121

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel